Cingulate Inc. (NASDAQ: CING) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT CINGULATE INC.

Cingulate Inc. (NASDAQ: CING)
Listen to this Section


$4.54
-0.2650 ( -5.52% ) 254.2K

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Clinical Trial Pipeline Stages


Drug Name Stage
CTx-1301DetailsAttention deficit hyperactivity disorder, Mental health Phase 3
CTx-1302DetailsMental health, Attention deficit hyperactivity disorder Phase 1/2

Market Data


Open $4.54
Previous Close $4.80
Volume 254.2K
Market Cap $65.73M
Day Range $4.34 - $4.85
52 Week Range $3.16 - $11.89
Shares Outstanding 13.47M
Change % -5.52%
Net Change ▼ -0.2650
Insider Ownership 0.00%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2021
CountryUnited States
UnderwriterAegis Capital Corp., Laidlaw & Company (UK), more

Insider Ownership Transactions

Total Amount Purchased: -6,779,783.00

Date Type Amount Purchased Purchaser
2024-07-02 Sale -1000.00 Brams Matthew
2024-07-02 Sale -1000.00 Silva Raul R.
2024-06-13 Sale -6926.00 Werth Peter J.
2024-06-13 Sale -5000.00 Lawrence Bryan Jay
2024-06-13 Sale -5000.00 Ervin Jeffrey S
2024-06-13 Sale -98944.00 Myers Laurie
2024-06-13 Sale -63324.00 Silva Raul R.
2024-06-13 Sale -217677.00 Schaffer Shane J.
2024-06-13 Sale -63324.00 Brams Matthew
2024-06-13 Sale -5000.00 ROBERTS JOHN A

SEC Filings


Form Type Description Pages Date
10-q Quarterly Reports 80 Aug 19, 2025
8-k 8K-related 14 Aug 15, 2025
nt Quarterly Reports 1 Aug 15, 2025
def Proxies and info statements 3 Aug 15, 2025
8-k 8K-related 13 Aug 08, 2025
8-k 8K-related 14 Aug 06, 2025
pre Proxies and info statements 3 Aug 05, 2025
8-k 8K-related 13 Jul 25, 2025
8-k 8K-related 15 Jul 22, 2025
4 Insider transactions 1 Jul 10, 2025

Latest News


× Before browsing our site, please accept our cookies policy